3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Glioblastoma
41
Glioma
10
Brain Neoplasms
9
Gliosarcoma
8
Astrocytoma
7
Neuroblastoma
6
Small Cell Lung Carcinoma
4
Oligodendroglioma
4
Neoplasms
4
Medulloblastoma
4
Sarcoma, Ewing
3
Sarcoma
3
Melanoma
3
Somatostatinoma
2
Rhabdomyosarcoma
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Neuroendocrine Tumors
2
Lung Neoplasms
2
Ependymoma
2
Diffuse Intrinsic Pontine Glioma
2
Desmoplastic Small Round Cell Tumor
2
Central Nervous System Neoplasms
2
Carcinoma, Neuroendocrine
2
Adenoma, Islet Cell
2
Supratentorial Neoplasms
1
Spinal Cord Neoplasms
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Interventions
lutetium Lu 177 dotatate
2
pasireotide
1
copper dotatate CU-64
1
amino-acid, glucose, and electrolyte solution
1
abemaciclib
1
Temozolomide
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Oxaliplatin
1
Octreotide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Everolimus
1
E-7386
1
Capecitabine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Gastro-enteropancreatic neuroendocrine tumor
×
Temozolomide
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled